Targeted Oncology1h
DSMB Approves Continued GOBLET Cohort 5 Enrollment in Pancreatic Cancer
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.
Targeted Oncology3h
Daratumumab Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Targeted Oncology19h
Therapies With Different Mechanisms of Action Available for Low-Risk MDS
Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...
Targeted Oncology21h
CEPHEUS Trial Results: Daratumumab-VRd in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.
Targeted Oncology23h
ASH 2024 Preview for Community Oncologists: The Show and After Show
Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...
Targeted Oncology23h
TERN-701 Shows Promising Early Results in Heavily Pre-Treated CML
TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...